Skip to main content

Table 4 Association of loss of vascular access patencya with attribution of ESRD to SLE vs. other causes, among 2010 U.S. incident hemodialysis patients who started dialysis with a permanent vascular access

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model

No. (%) with access revision within 1 year

Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD

Unadjusted

Adjusted for demographics

Adjusted for demographics + clinical

All patients

    

 SLE-attributed ESRD

21 (43.8 %)

0.70 (0.45-1.09)

0.81 (0.52-1.26)

0.88 (0.57-1.37)

 Other ESRD

7,169 (55.0 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.12

0.11

0.35

0.58

Among patients with AVFb

    

 SLE-attributed ESRD

19 (44.2 %)

0.74 (0.46-1.17)

0.86 (0.54-1.37)

0.94 (0.59-1.50)

 Other ESRD

5,735 (52.9 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.26

0.20

0.53

0.80

Among patients with AVGb

    

 SLE-attributed ESRD

c

0.54 (0.13-2.15)

0.57 (0.14-2.30)

0.61 (0.15-2.47)

 Other ESRD

1,434 (65.8 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.35

0.38

0.43

0.49

  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aDefined as a revision or placement of a new AVF, AVG, or catheter (see Table 1)
  3. bN = 10,890 and 2,183 for AVF and AVG, respectively
  4. cNot reportable due to cell size < 10